Gary Nachman

John Vandermosten

Justin Walsh

Boris Tolkachev

Thomas Flaten

François Brisebois

Brandon Folkes

- Achieve Life Sciences announced a **leadership transition**, with Dr. Cindy Jacobs resigning as Chief Medical Officer and President, effective **October 6, 2025**, and Dr. Mark Rubinstein appointed Interim Chief Medical Officer.  **[949858_4c004837efda4e17a39893cf2f149511]** 
- The company recently received **FDA acceptance** of its New Drug Application for cytisinicline, a plant-based treatment for nicotine dependence, and is progressing toward commercialization.  **[949858_4c004837efda4e17a39893cf2f149511]** 
- Achieve Life Sciences faces financial challenges typical of early-stage biotechs, including **zero revenue** and **ongoing losses**, with a **negative earnings per share of -1.46**.  **[949858_4c004837efda4e17a39893cf2f149511]** 
- The stock (ACHV) has an analyst rating of **'Buy'** with a **$10.00 price target**, although TipRanks’ AI Analyst rates it as **'Underperform'**.  **[949858_4c004837efda4e17a39893cf2f149511]**

ACHIEVE LIFE SCIENCES (ACHV)